- Home
- NTRA
NTRA
Natera Inc.
as 02-21-2025 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Upcoming Earnings Alert:
Get ready for potential market movements as Natera Inc. NTRA prepares to release earnings report on 27 Feb 2025.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 22.1B | IPO Year: | 2015 |
| Target Price: | $165.88 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $69.91 - $183.00 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,531,955,000 | Revenue Growth: | 54.94% |
| Revenue Growth (this year): | 56.11% | Revenue Growth (next year): | 9.76% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Feb 5 '25 | Sell | $177.77 | 1,632 | $290,120.64 | 149,768 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 31 '25 | Sell | $176.10 | 43,902 | $7,763,862.19 | 93,491 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jan 29 '25 | Sell | $166.31 | 4,773 | $791,693.97 | 216,752 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Jan 29 '25 | Sell | $166.38 | 4,030 | $668,453.90 | 143,200 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 29 '25 | Sell | $168.50 | 6,221 | $1,052,112.05 | 93,491 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Jan 29 '25 | Sell | $166.61 | 6,003 | $995,715.77 | 2,383,181 | |
| Sheena Jonathan | NTRA | Director | Jan 29 '25 | Sell | $169.88 | 1,217 | $203,612.70 | 259,940 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jan 29 '25 | Sell | $166.61 | 13,685 | $2,269,928.10 | 263,821 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 27 '25 | Sell | $161.87 | 1,442 | $233,416.54 | 93,491 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jan 22 '25 | Sell | $168.45 | 24,861 | $4,101,226.45 | 149,768 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Natera (NTRA) Surged on Blowout Quarterly Results
Business Wire
4 days ago
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
Investor's Business Daily
8 days ago
Schrodinger Stock Scores IBD Rating Upgrade
Business Wire
12 days ago
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Simply Wall St.
19 days ago
High Growth Tech Stocks to Watch in February 2025
Business Wire
19 days ago
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
Insider Monkey
25 days ago
Here’s Why Natera (NTRA) Surged in Q4
Medical Device Network
a month ago
Natera reports new data from Phase III study of colorectal cancer detection test
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.